Neratinib Approaches EU Approval for HER2+ Breast Cancer
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of neratinib, for the extended adjuvant treatment of adult patients with early stage hormone receptor–positive, HER2-overexpressed/amplified breast cancer following postoperative trastuzumab.
Source: OncLive